JP2018502572A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502572A5 JP2018502572A5 JP2017534345A JP2017534345A JP2018502572A5 JP 2018502572 A5 JP2018502572 A5 JP 2018502572A5 JP 2017534345 A JP2017534345 A JP 2017534345A JP 2017534345 A JP2017534345 A JP 2017534345A JP 2018502572 A5 JP2018502572 A5 JP 2018502572A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- bispecific antibody
- polypeptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562099236P | 2015-01-02 | 2015-01-02 | |
| US62/099,236 | 2015-01-02 | ||
| US201562200363P | 2015-08-03 | 2015-08-03 | |
| US62/200,363 | 2015-08-03 | ||
| US201562261609P | 2015-12-01 | 2015-12-01 | |
| US62/261,609 | 2015-12-01 | ||
| PCT/US2015/068238 WO2016109774A1 (en) | 2015-01-02 | 2015-12-31 | Bispecific antibodies against plasma kallikrein and factor xii |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020128994A Division JP7003347B2 (ja) | 2015-01-02 | 2020-07-30 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502572A JP2018502572A (ja) | 2018-02-01 |
| JP2018502572A5 true JP2018502572A5 (enExample) | 2019-02-14 |
| JP6744313B2 JP6744313B2 (ja) | 2020-08-26 |
Family
ID=56285069
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017534345A Active JP6744313B2 (ja) | 2015-01-02 | 2015-12-31 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
| JP2020128994A Active JP7003347B2 (ja) | 2015-01-02 | 2020-07-30 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
| JP2021150755A Active JP7241827B2 (ja) | 2015-01-02 | 2021-09-16 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
| JP2023035060A Active JP7635285B2 (ja) | 2015-01-02 | 2023-03-07 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020128994A Active JP7003347B2 (ja) | 2015-01-02 | 2020-07-30 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
| JP2021150755A Active JP7241827B2 (ja) | 2015-01-02 | 2021-09-16 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
| JP2023035060A Active JP7635285B2 (ja) | 2015-01-02 | 2023-03-07 | 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11390687B2 (enExample) |
| EP (2) | EP4670785A2 (enExample) |
| JP (4) | JP6744313B2 (enExample) |
| KR (2) | KR20240091031A (enExample) |
| CN (2) | CN114316061B (enExample) |
| AU (2) | AU2015373910B2 (enExample) |
| CA (1) | CA2972800A1 (enExample) |
| CO (1) | CO2017007123A2 (enExample) |
| EA (1) | EA201791527A1 (enExample) |
| IL (2) | IL298086B2 (enExample) |
| MX (2) | MX2017008541A (enExample) |
| NZ (1) | NZ771568A (enExample) |
| WO (1) | WO2016109774A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017008541A (es) | 2015-01-02 | 2017-12-04 | Dyax Corp | Anticuerpos biespecificos contra calicreina y factor xii del plasma. |
| BR112018001202A2 (en) * | 2015-07-21 | 2018-09-25 | Dyax Corp. | monoclonal antibody, nucleic acid, vector, host cell, pharmaceutical composition and method |
| JP7319916B2 (ja) * | 2016-09-16 | 2023-08-02 | 武田薬品工業株式会社 | 遺伝性血管性浮腫のｒｎａバイオマーカー |
| US11834506B2 (en) | 2017-02-08 | 2023-12-05 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| ES2955074T3 (es) | 2017-02-20 | 2023-11-28 | Dragonfly Therapeutics Inc | Proteínas que se unen a HER2, NKG2D Y CD16 |
| CN113004391A (zh) * | 2017-08-16 | 2021-06-22 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和egfr、ccr4或pd-l1的蛋白质 |
| KR20200067195A (ko) * | 2017-10-18 | 2020-06-11 | 리젠엑스바이오 인크. | 완전-인간 번역후 변형된 항체 치료제 |
| JP7394767B2 (ja) * | 2018-01-12 | 2023-12-08 | ジェンザイム・コーポレーション | ポリペプチドの定量化方法 |
| ES2986967T3 (es) | 2018-02-08 | 2024-11-13 | Dragonfly Therapeutics Inc | Combinaciones de dominios variables de anticuerpos dirigidas al receptor NKG2D |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| BR112020016939A2 (pt) * | 2018-02-20 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Proteínas de ligação multiespecíficas que se ligam a cd33, nkg2d, e cd16 e métodos de uso |
| JP7412001B2 (ja) * | 2018-06-08 | 2024-01-12 | 株式会社モダリス | 改変されたＣａｓ９タンパク質及びその用途 |
| KR20210044782A (ko) * | 2018-07-11 | 2021-04-23 | 모멘타 파머슈티컬스 인코포레이티드 | PD-L1 표적화 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법 |
| AU2019319906A1 (en) * | 2018-08-08 | 2021-03-04 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and a tumor-associated antigen |
| KR102835308B1 (ko) | 2018-08-08 | 2025-07-21 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| SG11202100883SA (en) | 2018-08-08 | 2021-02-25 | Dragonfly Therapeutics Inc | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| EP3870214A4 (en) * | 2018-10-24 | 2022-08-10 | Shire-NPS Pharmaceuticals, Inc. | Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions |
| CA3147735A1 (en) * | 2019-07-26 | 2021-02-04 | Janssen Biotech, Inc. | Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses |
| AU2021268340A1 (en) | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| US20230390418A1 (en) * | 2020-10-29 | 2023-12-07 | Regenxbio Inc. | Vectorized factor xii antibodies and administration thereof |
| WO2022156799A1 (zh) * | 2021-01-25 | 2022-07-28 | 成都康弘生物科技有限公司 | 一种抗体及其用途 |
| WO2022156798A1 (zh) * | 2021-01-25 | 2022-07-28 | 成都康弘生物科技有限公司 | 一种抗体及其用途 |
| US12377144B2 (en) | 2021-03-03 | 2025-08-05 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen |
| MX2023012489A (es) * | 2021-04-22 | 2023-11-22 | Guangdong Fapon Biopharma Inc | Polipeptido de fusion biespecifico multifuncional. |
| WO2024238407A2 (en) * | 2023-05-12 | 2024-11-21 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods of treating dilated cardiomyopathy and heart failure |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| US4963657A (en) | 1988-06-09 | 1990-10-16 | Temple University Of The Commonwealth System Of Higher Education | Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same |
| EP0454781B1 (en) | 1989-01-23 | 1998-12-16 | Chiron Corporation | Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof |
| GB8901859D0 (en) | 1989-01-27 | 1989-03-15 | Shield Diagnostics Limited | Diagnostic test |
| US5500349A (en) | 1989-01-27 | 1996-03-19 | Coagen Limited | Blood-coagulation factor XIIA β monoclonal antibody and immunoassay |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| ATE165516T1 (de) | 1989-03-21 | 1998-05-15 | Vical Inc | Expression von exogenen polynukleotidsequenzen in wirbeltieren |
| EP1001032A3 (en) | 1989-08-18 | 2005-02-23 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
| WO1991017258A1 (en) | 1990-05-10 | 1991-11-14 | Cetus Corporation | Inhibitors of factor xii activation and applications thereof |
| CA2115742A1 (en) | 1991-08-20 | 1993-03-04 | Ronald G. Crystal | Adenovirus mediated transfer of genes to the gastrointestinal tract |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| US6093399A (en) | 1992-03-05 | 2000-07-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
| FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| WO1993025234A1 (en) | 1992-06-08 | 1993-12-23 | The Regents Of The University Of California | Methods and compositions for targeting specific tissue |
| EP0644946A4 (en) | 1992-06-10 | 1997-03-12 | Us Health | VECTOR PARTICLES RESISTANT TO HUMAN SERUM INACTIVATION. |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| EP1024198A3 (en) | 1992-12-03 | 2002-05-29 | Genzyme Corporation | Pseudo-adenoviral vectors for the gene therapy of haemophiliae |
| US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
| AU6818094A (en) | 1993-04-22 | 1994-11-08 | Depotech Corporation | Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
| ES2249761T3 (es) | 1993-06-24 | 2006-04-01 | Advec Inc. | Vectores de adenovirus para terapia genica. |
| DE69433461T2 (de) | 1993-09-15 | 2004-11-18 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Rekombinanter Alphavirus Vektor |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| SK283703B6 (sk) | 1993-10-25 | 2003-12-02 | Canji, Inc. | Rekombinantný adenovírusový vektor a jeho použitie |
| KR100241300B1 (ko) | 1993-11-16 | 2000-03-02 | Sheldon A. Schaffer | 활성물질의 조절된 방출성을 갖는 소포 |
| AU2585395A (en) | 1994-05-09 | 1995-11-29 | Chiron Corporation | Retroviral vectors having a reduced recombination rate |
| WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| GB9609262D0 (en) | 1996-05-02 | 1996-07-03 | Isis Innovation | Peptide library and method |
| EP0953052B1 (en) | 1996-05-06 | 2009-03-04 | Oxford BioMedica (UK) Limited | Crossless retroviral vectors |
| AU3734900A (en) | 1999-03-09 | 2000-09-28 | University Of Southern California | Method of promoting myocyte proliferation and myocardial tissue repair |
| CN101260156A (zh) * | 2002-06-28 | 2008-09-10 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
| AU2005318464B2 (en) | 2004-12-23 | 2012-02-23 | Csl Behring Gmbh | Prevention of thrombus formation and/or stabilization |
| GB0500487D0 (en) | 2005-01-11 | 2005-02-16 | Axis Shield Diagnostics Ltd | Forms of factor XIIa |
| US7932021B2 (en) | 2005-07-28 | 2011-04-26 | American Diagnostica, Inc. | Lupus anticoagulant testing |
| GB0607515D0 (en) | 2006-04-13 | 2006-05-24 | Axis Shield Diagnostics Ltd | Anti-factor xlla therapy |
| TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子ｖｉｉ多肽和其用途 |
| TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子 |
| HRP20190605T1 (hr) | 2008-12-18 | 2019-05-31 | Oregon Health & Science University | Protutijela anti-fxi i postupci njihove uporabe |
| SI2521568T1 (sl) | 2010-01-06 | 2019-01-31 | Dyax Corp. | Proteini, ki vežejo plazemski kalikrein |
| EP3318633A1 (en) | 2010-11-17 | 2018-05-09 | Chugai Seiyaku Kabushiki Kaisha | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
| KR102502293B1 (ko) * | 2011-01-06 | 2023-02-21 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 |
| RU2660370C2 (ru) * | 2011-07-22 | 2018-07-05 | Цсл Беринг Гмбх | Ингибирующие моноклональные антитела против фактора xii/xiia и их применения |
| EP2548892A1 (en) * | 2011-07-22 | 2013-01-23 | CSL Behring GmbH | Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses |
| JP5653860B2 (ja) | 2011-07-28 | 2015-01-14 | 富士フイルム株式会社 | 管壁の硬度測定方法および装置 |
| WO2013051294A1 (ja) * | 2011-10-05 | 2013-04-11 | 中外製薬株式会社 | 糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子 |
| CN104011221B (zh) * | 2011-12-20 | 2019-01-08 | 米迪缪尼有限公司 | 用于双特异性抗体支架的经修饰的多肽 |
| EP2623110A1 (en) * | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
| LT2847228T (lt) | 2012-05-10 | 2018-11-12 | Bayer Pharma Aktiengesellschaft | Antikūnai, galintys jungtis prie koaguliacijos faktoriaus xi ir (arba) jo aktyvuotos formos faktoriaus xia, ir jų panaudojimas |
| US20140038204A1 (en) * | 2012-07-31 | 2014-02-06 | Baxter Healthcare S.A. | Selective measurement of active human protease coagulation factors |
| US9574013B2 (en) | 2012-12-07 | 2017-02-21 | Vanderbilt University | Antibodies against factor XII and uses thereof |
| TR201904638T4 (tr) * | 2013-01-20 | 2019-04-22 | Dyax Corp | pKal aracılı rahatsızlıkların değerlendirilmesi, analizi ve tedavisi. |
| EP3594244A1 (en) | 2013-03-15 | 2020-01-15 | Dyax Corp. | Anti-plasma kallikrein antibodies |
| EP3013366B1 (en) * | 2013-06-28 | 2021-08-25 | CSL Behring GmbH | Combination therapy using a factor xii inhibitor and a c1-inhibitor |
| CA2918795A1 (en) | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
| MX2017008541A (es) | 2015-01-02 | 2017-12-04 | Dyax Corp | Anticuerpos biespecificos contra calicreina y factor xii del plasma. |
| BR112018001202A2 (en) * | 2015-07-21 | 2018-09-25 | Dyax Corp. | monoclonal antibody, nucleic acid, vector, host cell, pharmaceutical composition and method |
| EP3263803B1 (en) | 2016-06-30 | 2019-08-14 | ABB Schweiz AG | Substation |
-
2015
- 2015-12-31 MX MX2017008541A patent/MX2017008541A/es unknown
- 2015-12-31 CN CN202210054884.3A patent/CN114316061B/zh active Active
- 2015-12-31 US US15/541,066 patent/US11390687B2/en active Active
- 2015-12-31 CN CN201580075633.1A patent/CN107405399B/zh active Active
- 2015-12-31 IL IL298086A patent/IL298086B2/en unknown
- 2015-12-31 EA EA201791527A patent/EA201791527A1/ru unknown
- 2015-12-31 NZ NZ771568A patent/NZ771568A/en unknown
- 2015-12-31 KR KR1020247017566A patent/KR20240091031A/ko active Pending
- 2015-12-31 EP EP25204079.5A patent/EP4670785A2/en active Pending
- 2015-12-31 JP JP2017534345A patent/JP6744313B2/ja active Active
- 2015-12-31 IL IL253180A patent/IL253180B2/en unknown
- 2015-12-31 WO PCT/US2015/068238 patent/WO2016109774A1/en not_active Ceased
- 2015-12-31 KR KR1020177021610A patent/KR102670705B1/ko active Active
- 2015-12-31 AU AU2015373910A patent/AU2015373910B2/en active Active
- 2015-12-31 CA CA2972800A patent/CA2972800A1/en active Pending
- 2015-12-31 EP EP15876336.7A patent/EP3240570B1/en active Active
-
2017
- 2017-06-26 MX MX2024000317A patent/MX2024000317A/es unknown
- 2017-07-17 CO CONC2017/0007123A patent/CO2017007123A2/es unknown
-
2020
- 2020-07-30 JP JP2020128994A patent/JP7003347B2/ja active Active
-
2021
- 2021-09-16 JP JP2021150755A patent/JP7241827B2/ja active Active
-
2022
- 2022-02-17 AU AU2022201076A patent/AU2022201076B2/en active Active
- 2022-06-13 US US17/838,769 patent/US12240918B2/en active Active
-
2023
- 2023-03-07 JP JP2023035060A patent/JP7635285B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502572A5 (enExample) | ||
| JP2020186248A5 (enExample) | ||
| CN106459220B (zh) | 适用于高通量筛选的新的双特异性形式 | |
| US11286312B2 (en) | Multispecific antibodies | |
| JP2016533174A5 (enExample) | ||
| KR102282691B1 (ko) | 개변된 헬퍼 파지를 사용하여 항원 결합 분자를 제작하는 방법 | |
| JP7203800B2 (ja) | ヌクレオチド・ライブラリー | |
| JP7549961B2 (ja) | 少なくともｃｄ３及びｈｓａを標的とするヘテロ二量体多重特異性抗体フォーマット | |
| JP7209464B2 (ja) | ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体 | |
| JP2017512063A5 (enExample) | ||
| JP2017529067A5 (enExample) | ||
| CN108473556A (zh) | 多特异性抗体 | |
| CN108473554A (zh) | 多特异性抗体 | |
| JP2020500510A5 (enExample) | ||
| JP2014518883A5 (enExample) | ||
| JP2014521313A5 (enExample) | ||
| KR20190111946A (ko) | 1가 항-프로페르딘 항체 및 항체 단편 | |
| JP2019506839A5 (enExample) | ||
| JP2018512124A5 (enExample) | ||
| CN111526887A (zh) | 用于使血清中的蛋白质半衰期增加的组合物和方法 | |
| RU2017134043A (ru) | Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью | |
| JP6247646B2 (ja) | ヒト化抗ｈｍｇｂ１抗体もしくはその抗原結合性断片 | |
| Henry et al. | A disulfide-stabilized human VL single-domain antibody library is a source of soluble and highly thermostable binders | |
| Aoki et al. | Engineering a low-immunogenic mirror-image VHH against vascular endothelial growth factor | |
| CN107073093A (zh) | 亲和蛋白及其用途 |